Theriva Biologics leverages FDA and EMA feedback to optimize VCN-01 pivotal trial
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.
Pharma & Biotech
Pharma & Biotech
Avalyn Pharma moves AP02 into Phase 2, exploring whether nebulized delivery can improve risk benefit balance in IPF
Avalyn Pharma advances inhaled AP02 into Phase 2 trials for IPF. Learn how lung targeted delivery could reshape antifibrotic treatment.
Pharma & Biotech
Harbour BioMed HBM9378 Phase I data: does long-acting TSLP inhibition change asthma treatment economics?
Harbour BioMed’s HBM9378 Phase I data shows long half-life and safety. Find out what this means for asthma, COPD, and TSLP competition.
Pharma & Biotech
Dizal’s Zegfrovy challenges chemo dominance in rare EGFR lung cancer mutation
Zegfrovy Phase 3 results could redefine EGFR exon20ins lung cancer treatment. Discover what this means for frontline therapy and future care strategies.
Pharma & Biotech
How Sensorion’s SENS-501 data could reshape gene therapy for congenital hearing loss treatment
Sensorion reports promising gene therapy data for congenital deafness. Discover what it means for hearing loss treatment and future clinical breakthroughs.
Pharma & Biotech
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Pharma & Biotech
How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
Pharma & Biotech
How HUTCHMED (China) Limited is positioning HMPL-760 against established BTK therapies in lymphoma care
Can HMPL-760 improve outcomes in relapsed DLBCL? Explore how HUTCHMED is advancing next-gen BTK inhibitors in China.
Pharma & Biotech
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Pharma & Biotech
Will Apogee Therapeutics’ APEX data shift competitive dynamics against Dupixent and Ebglyss?
Apogee Therapeutics prepares to release 52-week APEX data for zumilokibart. Discover what it could mean for eczema treatment and competition.